Evidence map›Paper›PMID 32429244›Full record

ArticleInternational journal of molecular sciences2020

The Apolipoprotein A-I Mimetic L-4F Attenuates Monocyte Activation and Adverse Cardiac Remodeling after Myocardial Infarction.

Tariq Hamid, Mohamed Ameen Ismahil, Shyam S Bansal, Bindiya Patel, Mehak Goel, C Roger White, G M Anantharamaiah, Sumanth D Prabhu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. HDL Composition, Heart Failure, and Its Comorbidities.Frontiers in cardiovascular medicine · 2022
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tariq HamidDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Mohamed Ameen IsmahilDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Shyam S BansalDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Bindiya PatelDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Mehak GoelDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
C Roger WhiteDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
G M AnantharamaiahDivision of Gerontology, Geriatrics, and Palliative Care, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Sumanth D PrabhuDivision of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
University of Alabama at Birmingham · US

Funding

Cardiac Mesenchymal Stem Cells and Myocardial Fibrosis: Role of Platelet Derived Growth Factor Receptor SignalingR01HL137046 · NHLBI · WASHINGTON UNIVERSITY · PI HAMID, TARIQ · 2018 to 2021
$1.5M
Splenic Marginal Zone Macrophages in Chronic Ischemic Heart FailureR01HL125735 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PRABHU, SUMANTH D · 2015 to 2018
$1.5M
Pathological TNFR1 Expressing CD4+ T-cells are Critical for HF progressionR00HL132123 · NHLBI · OHIO STATE UNIVERSITY · PI BANSAL, SHYAM SUNDER · 2018 to 2020
$738k
Role of Regulatory T-Lymphocytes in Chronic Heart FailureI01BX002706 · VA · BIRMINGHAM VA MEDICAL CENTER · PI PRABHU, SUMANTH D · 2015 to 2018
–
BLRD VA I01 BX002706NHLBI NIH HHS R00 HL132123NHLBI NIH HHS R01 HL125735NHLBI NIH HHS R01 HL137046NIH HHS DK108836NIH HHS GM115367NIH HHS HL125735NIH HHS HL 132123NIH HHS HL137046
6 · The paper itself

Abstract

Excessive inflammation after myocardial infarction (MI) can promote infarct expansion and adverse left ventricular (LV) remodeling. L-4F, a mimetic peptide of apolipoprotein A-I (apoA-I), exhibits anti-inflammatory and anti-atherogenic properties; however, whether L-4F imparts beneficial effects after myocardial infarction (MI) is unknown. Here we demonstrate that L-4F suppresses the expansion of blood, splenic, and myocardial pro-inflammatory monocytes and macrophages in a mouse model of reperfused MI. Changes in immune cell profiles were accompanied by alleviation of post-MI LV remodeling and dysfunction. In vitro, L-4F also inhibited pro-inflammatory and glycolytic gene expression in macrophages. In summary, L-4F treatment prevents prolonged and excessive inflammation after MI, in part through modulation of pro-inflammatory monocytes and macrophages, and improves post-MI LV remodeling. These data suggest that L-4F could be a used as a therapeutic adjunct in humans with MI to limit inflammation and alleviate the progression to heart failure.

Indexed as

AnimalsApolipoprotein A-ICell PlasticityInflammationMacrophage ActivationMacrophagesMaleMiceMice, Inbred C57BLMonocytesMyocardial InfarctionPeptidesRAW 264.7 CellsSystoleVentricular Dysfunction, LeftVentricular RemodelingApolipoprotein A-IL-4F peptidePeptidescardiac remodelingheart failureinflammationmacrophage polarity

Identifiers

PMID32429244
PMCPMC7279031
OpenAlexW3024032131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.